Publications by authors named "Rebecca S Parker"
Little is known about the efficacy of COVID-19 vaccines during acute lymphoblastic leukemia therapy (ALL); data for COVID-19 vaccine immune responses in pediatric leukemia remain sparse. We conducted a single center study of patients aged 5-25 years undergoing ALL chemotherapy who received COVID-19 vaccination. Twenty-one patients were enrolled; efficacy was evaluable in 20.
View Article and Find Full Text PDFArticle Synopsis
- Recurrent brain tumors are a major cause of cancer-related deaths in children, and the study focused on indoximod, which inhibits a metabolic checkpoint called IDO and may enhance anti-tumor immunity post-chemotherapy.
- A phase I trial was conducted with 81 pediatric patients, using indoximod in combination with temozolomide or radiation, to assess its safety and determine the appropriate dosage.
- Results showed a median overall survival of 13.3 months for recurrent cases, with patients who responded to treatment experiencing significantly longer survival, and the findings indicate potential for further trials to evaluate indoximod's effectiveness in treating pediatric brain tumors.
Pediatric oncology patients are at risk for poor outcomes with respiratory viral infections. Outcome data for COVID-19 in children and young adults with cancer are needed; data are sparse for obese/overweight and adolescent and young adult subgroups. We conducted a single center cohort study of COVID-19 outcomes in patients younger than 25 years with cancer.
View Article and Find Full Text PDF